Literature DB >> 12949531

Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment.

Andrew M Tager1, Shannon K Bromley, Benjamin D Medoff, Sabina A Islam, Scott D Bercury, Erik B Friedrich, Andrew D Carafone, Robert E Gerszten, Andrew D Luster.   

Abstract

Leukotriene B4 (LTB4) was originally described as a potent lipid myeloid cell chemoattractant, rapidly generated from innate immune cells, that activates leukocytes through the G protein-coupled receptor BLT1. We report here that BLT1 is expressed on effector CD4+ T cells generated in vitro as well as in vivo when effector T cells migrate out of the lymphoid compartment and are recruited into peripheral tissues. BLT1 mediated LTB4-induced T helper type 1 (T(H)1) and T(H)2 cell chemotaxis and firm adhesion to endothelial cells under flow, as well as early CD4+ and CD8+ T cell recruitment into the airway in an asthma model. Our findings show that the LTB4-BLT1 pathway is involved in linking early immune system activation and early effector T cell recruitment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949531     DOI: 10.1038/ni970

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  119 in total

1.  NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation.

Authors:  Oliver Haworth; Manuela Cernadas; Bruce D Levy
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

2.  Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis.

Authors:  Richard C Chou; Nancy D Kim; Christian D Sadik; Edward Seung; Yinan Lan; Michael H Byrne; Bodduluri Haribabu; Yoichiro Iwakura; Andrew D Luster
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

3.  Blocking the leukotriene B4 receptor 1 inhibits late-phase airway responses in established disease.

Authors:  Koichi Waseda; Nobuaki Miyahara; Arihiko Kanehiro; Genyo Ikeda; Hikari Koga; Yasuko Fuchimoto; Etsuko Kurimoto; Yasushi Tanimoto; Mikio Kataoka; Mitsune Tanimoto; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2011-03-18       Impact factor: 6.914

Review 4.  Regulation of immunity by lysosphingolipids and their G protein-coupled receptors.

Authors:  Edward J Goetzl; Hugh Rosen
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 5.  Mast cell survival and activation by IgE in the absence of antigen: a consideration of the biologic mechanisms and relevance.

Authors:  Toshiaki Kawakami; Jiro Kitaura
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

6.  Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4.

Authors:  Hong Qiu; Anne-Sofie Johansson; Mattias Sjöström; Min Wan; Oliver Schröder; Jan Palmblad; Jesper Z Haeggström
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-19       Impact factor: 11.205

7.  Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells.

Authors:  Y You; Y Li; M Li; M Lei; M Wu; Y Qu; Y Yuan; T Chen; H Jiang
Journal:  Clin Exp Immunol       Date:  2017-10-23       Impact factor: 4.330

Review 8.  Leukotriene receptors as potential therapeutic targets.

Authors:  Takehiko Yokomizo; Motonao Nakamura; Takao Shimizu
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

9.  The nuclear membrane organization of leukotriene synthesis.

Authors:  Asim K Mandal; Phillip B Jones; Angela M Bair; Peter Christmas; Douglas Miller; Ting-ting D Yamin; Douglas Wisniewski; John Menke; Jilly F Evans; Bradley T Hyman; Brian Bacskai; Mei Chen; David M Lee; Boris Nikolic; Roy J Soberman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 10.  Targeting cells in motion: migrating toward improved therapies.

Authors:  Jason W Griffith; Andrew D Luster
Journal:  Eur J Immunol       Date:  2013-05-13       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.